$INDV News
Last published 2w ago
- 2w agoINDVIndivior Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoINDVIndivior Reports Third Quarter 2026 Financial ResultsGlobeNewswireQ3’26 Total Net Revenue of $356 Million, Up 13% YoYRecord Quarterly Total SUBLOCADE® Net Revenue of $267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Income of
- 2w agoSPGIHURNINDVSUPNUpdated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600PR NewswireNEW YORK, Oct. 28, 2026 /PRNewswire/ -- Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3,
- 2w agoSPGIHURNINDVSUPN+4MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600PR NewswireNEW YORK, Oct. 22, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: MSG Rangers Inc. (NYSE:MSGR) will be added to the S&P SmallCap 600 effective prior to
- 3w agoINDVIndivior to Report Third Quarter 2026 Financial ResultsGlobeNewswireRICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results
- 1mo agoINDVIndivior Pharmaceuticals, Inc. Declares Special Cash DividendGlobeNewswireRICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) ("Indivior") today announced that its Board of Directors declared a special cash dividend (the "Special
- 3mo agoINDVJoint Supernus and Indivior Conference Call and Webcast - INDIVIOR PHARMACEUTICALS INCEarnings Call TranscriptsGood day and welcome to the conference call and webcast to discuss the merger of Supernus Pharmaceuticals and Indivior Pharmaceutical. At this time, all participants are in a listen-only mode. After the speaker presentat
- 3mo agoINDVIndivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 GuidanceGlobeNewswire• Q2’26 Total Net Revenue of $343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record
- 3mo agoSUPNINDVSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant ScaleGlobeNewswireCombines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenuesEnhanced financial position and free cash flow generation enabling
- 3mo agoINDVIndivior to Report Second Quarter 2026 Financial Results and Host WebcastGlobeNewswireRICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S.
- 5mo agoINDVNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare UtilizationGlobeNewswireCompared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.In a separate study, patients receiving monthly
- 6mo agoINDVIndivior to Participate in Upcoming Investor ConferencesGlobeNewswireRICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare
- 6mo agoINDVIndivior Announces $175 Million Accelerated Share RepurchaseGlobeNewswireRICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement ("the ASR") with Barclays
- 6mo agoINDVIndivior Pharmaceuticals, Inc. Q1 2026 Financial Results - INDIVIOR PHARMACEUTICALS INCEarnings Call TranscriptsThanks, Nadia, and welcome to Indivior's first quarter 2026 results conference call. I'm joined today by Joe Schifoni, Chief Executive Officer, Pat Berry, Chief Commercial Officer, Ryan Preba, Chief Financial Officer, an
- 6mo agoINDVIndivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 GuidanceGlobeNewswireQ1'26 Total Net Revenue of $317 Million, Up 19% YoYQ1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 MillionRecord
- 6mo agoINDVIndivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use DisorderGlobeNewswireA collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence aloneOf all MOUD, monthly extended-release
- 7mo agoINDVSurvey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication MisuseGlobeNewswireRICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders
- 7mo agoINDVIndivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30thGlobeNewswireRICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S.
- 7mo agoINDVNew Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional FacilitiesGlobeNewswireModel estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior
- 8mo agoINDVIndivior Prices Upsized $450.0 Million Convertible Senior Notes OfferingGlobeNewswireRICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes
- 8mo agoINDVIndivior Pharmaceuticals, Inc. Fourth Quarter and Full Year 2025 Results - INDIVIOR PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone. I am joined today by Joe Schifoni, Chief Executive Officer, Pat Berry, Chief Commercial Officer, and Ryan Previn, Chief Financial Officer. We're also joined by Christian Heidretter, our Chief Scie
- 8mo agoINDVIndivior Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswireGenerated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and
- 8mo agoINDVIndivior to Participate in Upcoming Investor ConferencesGlobeNewswireRICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global
- 9mo agoINDVIndivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰGlobeNewswireRICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026,
- 9mo agoINDVIndivior Announces Completion of Redomiciliation to the United StatesGlobeNewswireRICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior
- 10mo agoINDVIndivior Provides Full-Year 2026 Financial Guidance and Business UpdateGlobeNewswireTotal Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range
- 10mo agoINDVIndivior Announces Inclusion in the S&P SmallCap 600® IndexPR NewswireIndivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today....
- 11mo agoINDVNew Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk PopulationsPR NewswireIndivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found...
- 11mo agoINDVIndivior Concludes Legacy U.S. Department of Justice MatterPR NewswireIndivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the...
- 11mo agoINDVIndivior to Participate in the Piper Sandler 37th Annual Healthcare ConferencePR NewswireIndivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th...
- 1y agoINDVIndivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable BuprenorphinePR NewswireIndivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week,...
- 1y agoINDVIndivior PLC Q3 Results 2025 - INDIVIOR PHARMACEUTICALS INCEarnings Call TranscriptsWelcome to Indivior's Third Quarter 2025 Earnings Conference Call. I'm joined today by Joe Schifoni, Chief Executive Officer, Patrick Berry, Chief Commercial Officer, and Ryan Preblik, Chief Financial Officer. We're also
- 1y agoINDVIndivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial GuidancePR NewswireIndivior PLC (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update. "In...
- 1y agoINDVIndivior to Participate in the Stifel 2025 Healthcare ConferencePR NewswireIndivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference: Stifel 2025 Healthcare Conference –...
- 1y agoINDVIndivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30thPR NewswireIndivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m....
- 1y agoINDVClinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder TreatmentPR NewswireIndivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two...
- 1y agoINDVIndivior Proposes New Corporate Structure to Achieve U.S. DomiciliationPR NewswireIndivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S....
- 1y agoINDVIndivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoINDVIndivior to Participate in Upcoming Investor EventsPR NewswireIndivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events: Morgan Stanley 23rd Annual Global Healthcare...
- 1y agoINDVIndivior PLC (INDV) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoINDVIndivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial GuidancePR NewswireIndivior PLC (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2025, and provided a business update....
- 1y agoINDVIndivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be MaintainedPR NewswireFurther to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's...
- 1y agoINDVIndivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use DisorderPR NewswireIndivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports,...
- 1y agoINDVIndivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl UsersPR NewswireIndivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post...
- 1y agoINDVIndivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be MaintainedPR NewswireIndivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary...
- 1y agoINDVIndivior Announces Patrick Barry as Chief Commercial OfficerPR NewswireIndivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry...
- 1y agoINDVIndivior to Participate in Upcoming Investor EventsPR NewswireIndivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference –...
- 1y agoINDVNew Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After PregnancyPR NewswireIndivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder ...
- 1y agoINDVIndivior Announces Q1 2025 Financial ResultsPR NewswireIndivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor...
- 1y agoINDVIndivior Announces Joseph Ciaffoni Appointed Chief Executive OfficerPR NewswireIndivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive...